Northern Trust Corp Sells 8,836 Shares of Kewaunee Scientific Co. (NASDAQ:KEQU)

Northern Trust Corp decreased its holdings in Kewaunee Scientific Co. (NASDAQ:KEQU - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 278,952 shares of the technology company's stock after selling 8,836 shares during the period. Northern Trust Corp owned about 9.72% of Kewaunee Scientific worth $17,259,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of KEQU. JPMorgan Chase & Co. increased its holdings in shares of Kewaunee Scientific by 18,000.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock worth $30,000 after purchasing an additional 900 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of Kewaunee Scientific in the 4th quarter worth $36,000. Morgan Dempsey Capital Management LLC bought a new stake in shares of Kewaunee Scientific in the 4th quarter worth $106,000. Barclays PLC bought a new stake in shares of Kewaunee Scientific in the 3rd quarter worth $121,000. Finally, Wedbush Securities Inc. bought a new stake in shares of Kewaunee Scientific in the 4th quarter worth $262,000. Institutional investors own 32.69% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Kewaunee Scientific from a "buy" rating to a "hold" rating in a report on Friday, March 14th.

Kewaunee Scientific Stock Performance

Shares of KEQU opened at $37.06 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.64 and a quick ratio of 2.13. Kewaunee Scientific Co. has a one year low of $30.33 and a one year high of $71.33. The firm has a market capitalization of $105.81 million, a P/E ratio of 5.87 and a beta of 0.47. The business has a fifty day moving average of $38.01 and a 200 day moving average of $47.41.

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 EPS for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The company had revenue of $67.17 million during the quarter.

Insider Buying and Selling

In related news, CEO Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock in a transaction on Monday, March 24th. The stock was sold at an average price of $45.63, for a total transaction of $136,890.00. Following the transaction, the chief executive officer now directly owns 37,916 shares in the company, valued at approximately $1,730,107.08. The trade was a 7.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Keith M. Gehl bought 1,000 shares of the stock in a transaction that occurred on Friday, April 4th. The shares were bought at an average price of $35.00 per share, for a total transaction of $35,000.00. Following the completion of the transaction, the director now directly owns 18,500 shares of the company's stock, valued at $647,500. This represents a 5.71% increase in their position. The disclosure for this purchase can be found here. Insiders sold 11,057 shares of company stock valued at $440,326 over the last 90 days. Company insiders own 14.20% of the company's stock.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.